mt-sRNA has sensitivity of 94 percent for detecting colorectal cancer, 46 percent for advanced adenomas<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 24, 2023 (HealthDay News) — A noninvasive, multitarget stool RNA (mt-sRNA) test has high sensitivity for detecting colorectal neoplasia, according to a study published online Oct. 23 in the Journal of the American Medical Association <\/em>to coincide with the annual meeting of the American College of Gastroenterology, held from Oct. 20 to 25 in Vancouver, British Columbia, Canada.<\/p>\n Erica K. Barnell, M.D., Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues conducted a phase 3 clinical trial to assess the sensitivity and specificity of a noninvasive mt-sRNA test (ColoSense) compared with results from colonoscopy. A total of 8,920 participants were identified; all completed the mt-sRNA test, which included a fecal immunochemical test (FIT), concentration of eight RNA transcripts, and participant-reported smoking status. Stool samples were collected before completion of colonoscopy. The results from mt-sRNA were compared to the index lesions seen on colonoscopy. Patients aged 45 years and older were enrolled from 49 U.S. states; colonoscopies were obtained at more than 3,800 different endoscopy centers.<\/p>\n The researchers found that 0.40 percent of the eligible patients had colorectal cancer and 6.8 percent had advanced adenomas. The sensitivity of the mt-sRNA test for detecting colorectal cancer and advanced adenomas was 94 and 46 percent, respectively; specificity for no lesions on colonoscopy was 88 percent. Compared with results of the FIT, significant improvement in sensitivity was seen for the mt-sRNA test for colorectal cancer (94 versus 78 percent) and advanced adenomas (46 versus 29 percent).<\/p>\n “The mt-sRNA test can be an effective noninvasive test that is sensitive for colorectal cancer and advanced adenomas, with a comparable level of false-positive results compared with existing molecular screening tests,” the authors write.<\/p>\n Several authors disclosed ties to medical device companies, including Geneoscopy, which developed ColoSense and funded the clinical trial.<\/p>\n Abstract\/Full Text<\/a><\/p>\n